MedPath

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Phase 2
Recruiting
Conditions
AML
MDS
Interventions
Registration Number
NCT06717958
Lead Sponsor
Technische Universität Dresden
Brief Summary

maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days

Detailed Description

Determination of the efficacy of Ivosidenib to improve event-free survival when given as maintenance therapy following alloSCT.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
76
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
IvosidenibIvosidenib 250 MG (milligram)-
Primary Outcome Measures
NameTimeMethod
event-free survival24 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (12)

Universitätsklinikum Aachen

🇩🇪

Aachen, Germany

Technische Universitaet Dresden, Medizinische Klinik und Poliklinik I

🇩🇪

Dresden, Germany

Universitätsklinikum Essen

🇩🇪

Essen, Germany

Martin-Luther-Universitaet Halle-Wittenberg

🇩🇪

Halle, Germany

University Medical Center Hamburg-Eppendorf

🇩🇪

Hamburg, Germany

Universitätsklinikum Jena

🇩🇪

Jena, Germany

Universitätsklinikum Schleswig-Holstein

🇩🇪

Kiel, Germany

Universität Leipzig

🇩🇪

Leipzig, Germany

Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

🇩🇪

München, Germany

Universität Münster

🇩🇪

Münster, Germany

Scroll for more (2 remaining)
Universitätsklinikum Aachen
🇩🇪Aachen, Germany
Edgar Jost
Contact
+49241800
info@ukaachen.de
© Copyright 2025. All Rights Reserved by MedPath